Fig. 2: Pharmacological inhibition of SCD remodels the immune cell composition of the TME. | Communications Biology

Fig. 2: Pharmacological inhibition of SCD remodels the immune cell composition of the TME.

From: Targeting SCD triggers lipotoxicity of cancer cells and enhances anti-tumor immunity in breast cancer brain metastasis mouse models

Fig. 2

A Schematic of treatment and tissue processing for single cell RNA sequencing (scRNAseq) in a syngeneic mouse model of breast cancer brain metastasis (BCBM). FACS, fluorescent-activated cell sorting. This schematic was created with BioRender.com B Luciferase assay from blood collected over time from BCBM-bearing mice treated with vehicle (control; n = 8) or SCDi (50 mg/kg; n = 8) to measure tumor volume. C Uniform manifold approximation and projection (UMAP) of tumor cells in BCBM treated with control (n = 3) and SCDi (n = 3). D Histogram showing proportions of tumor cell subclusters in control and SCDi-treated tumors. E Pathway analysis (MSigDB) of differentially expressed genes (DEGs) in tumor cells (SCDi vs control). F Heatmap representing DEGs belonging to G2-M checkpoint, TGF-beta signaling, and TNF-alpha signaling via NF-kB pathways in control and SCDi-treated tumors. G UMAP of immune cells in control and SCDi-treated tumors. H Dot plot of average expression of canonical marker genes for the main immune cell subtypes. I Histogram showing cell frequency of immune cells in control and SCDi-treated tumors. *p < 0.05.

Back to article page